Drug spending hits $24.8 billion

Spending on New Drug Development

This paper replicates DiMasi et al (2003, 2004) estimates of expenditure on new drug development using publicly available data. The paper estimates that average expenditure on drugs in human clinical trials is around $25m per year, with $18m per year on drugs in Phase 1, $33m on drugs in Phase 2 and $19m per year on drugs in Phase 3 of the human clinical trials. The paper’s estimated expenditur...

Sources of variation in provincial drug spending.

A New Focus on Prescription Drug Spending.

Explaining drug spending trends : does perception match

Several recent studies have made clear that drug expenditures are rising more rapidly than other health care spending. What has not been clear, however, is how much drug spending is driven by price rather than volume and whether volume increases are appropriate. This DataWatch takes a closer look at the components and drivers of drug spending using large claims databases from managed care and e...

MarketWatch Spending On Postapproval Drug Safety

Withdrawals of high-profile pharmaceuticals have focused attention on postapproval safety surveillance. There have been no systematic assessments of spending on postapproval safety. We surveyed drug manufacturers regarding safety efforts. Mean spending on postapproval safety per company in 2003 was $56 million (0.3 percent of sales). Assuming a constant safety-to-sales ratio, we estimated that ...